We're taking a closer look at Zimmer Biomet today, as the chatter surrounding the stock has increased notably in the last few weeks. Today, its shares moved -0.4% compared to 0.0% for the S&P 500. Increased investor interest and volatility surrounding the stock are not reason enough to buy in -- you should first perform your own due diligence. Here are some figures that can get you started:
-
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
-
Zimmer Biomet has moved -8.1% over the last year compared to 15.0% for the S&P 500 -- a difference of -23.1%
-
ZBH has an average analyst rating of hold and is -9.22% away from its mean target price of $129.38 per share
-
Its trailing 12 month earnings per share (EPS) is $2.27
-
Zimmer Biomet has a trailing 12 month Price to Earnings (P/E) ratio of 51.7 while the S&P 500 average is 15.97
-
Its forward earnings per share (EPS) is $7.95 and its forward P/E ratio is 14.8
-
ZBH has a Price to Earnings Growth (PEG) ratio of 2.27, which shows the company is potentially overvalued when we factor growth into the price to earnings calculus.
-
The company has a Price to Book (P/B) ratio of 1.96 in contrast to the S&P 500's average ratio of 2.95
-
Zimmer Biomet is part of the Health Care sector, which has an average P/E ratio of 30.21 and an average P/B of 4.08
-
Zimmer Biomet has on average reported free cash flows of $1.26 Billion over the last four years, during which time they have grown by an an average of -6.6%